Crescent Biopharma, Inc. — Revenue by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/880729f1-4cfe-4ef6-ae9f-6ff80f3a53ae/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $10.8M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-011983 |
| FY 2023 | $10.0k | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-004013 |
| FY 2022 | $75.0k | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-004864 |
| FY 2021 | $1.2M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002737 |
| FY 2020 | $10.2M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002222 |
| FY 2016 | $18.5k | 2016-01-01 – 2016-12-31 | evidence 0001558370-19-001537 |
| FY 2015 | $20.1M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-003688 |
| FY 2014 | $15.0M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-093802 |
| FY 2013 | $23.6M | 2003-05-21 – 2014-03-31 | evidence 0001193125-14-192508 |
| FY 2012 | $15.3M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-093802 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Crescent Biopharma, Inc. — all facts · Net Income · Operating Income